伊布替尼通过靶向BTK和BLK抑制前B细胞受体阳性B细胞急性淋巴细胞白血病进展
在B-ALL临床前模型中,前B细胞受体阳性(pre-BCR+)ALL细胞对治疗相关浓度的伊布替尼高度敏感;伊布替尼抑制自主及诱导性pre-BCR信号、降低PI3K/Akt活性、减少BCL6并抑制迁移,CRISPR-Cas9证实BTK与BLK均为相关靶点,小鼠异种移植中显著延长生存,与地塞米松或长春新碱联用具协同活性。
要点
- pre-BCR+ ALL细胞对治疗相关浓度的伊布替尼高度敏感。
- CRISPR-Cas9证实BTK和BLK均为伊布替尼在pre-BCR+ ALL中的相关靶点。
- 伊布替尼与地塞米松或长春新碱联用对pre-BCR+ ALL显示协同活性。
核心结论
- 这些数据证实伊布替尼是pre-BCR+ ALL有前景的靶向药物,并强调伊布替尼对替代激酶靶点作用的重要性。
研究设计与样本
- 在B-ALL的临床前模型中研究伊布替尼的活性及作用机制。
主要发现
- pre-BCR+ ALL细胞对治疗相关浓度的伊布替尼高度敏感。
- 伊布替尼阻断自主及诱导性pre-BCR信号,导致PI3K/Akt信号失活。
- 伊布替尼调节pre-BCR调节因子(PTPN6、CD22、CD72和PKCβ)的表达并大幅降低BCL6水平。
- 伊布替尼抑制ALL细胞向CXCL12及骨髓基质细胞下迁移并降低CD44表达。
- CRISPR-Cas9基因编辑揭示BTK和B淋巴细胞激酶(BLK)均为伊布替尼在pre-BCR+ ALL中的相关靶点。
关键数值与推荐
- pre-BCR+ ALL细胞对治疗相关浓度的伊布替尼高度敏感。
- 伊布替尼与地塞米松或长春新碱联用对pre-BCR+ ALL显示协同活性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeting B-cell receptor (BCR) signaling is a successful therapeutic strategy in mature B-cell malignancies. Precursor BCR (pre-BCR) signaling, which is critical during normal B lymphopoiesis, also plays an important role in pre-BCR+ B cell acute lymphoblastic leukemia (B-ALL). Here, we investigated the activity and mechanism of action of the BTK inhibitor ibrutinib in preclinical models of B-ALL. Pre-BCR+ ALL cells were exquisitely sensitive to ibrutinib at therapeutically relevant drug concentrations. In pre-BCR+ ALL, ibrutinib thwarted autonomous and induced pre-BCR signaling, resulting in deactivation of PI3K/Akt signaling. Ibrutinib modulated the expression of pre-BCR regulators (PTPN6, CD22, CD72, and PKCβ) and substantially reduced BCL6 levels. Ibrutinib inhibited ALL cell migration toward CXCL12 and beneath marrow stromal cells and reduced CD44 expression. CRISPR-Cas9 gene editing revealed that both BTK and B lymphocyte kinase (BLK) are relevant targets of ibrutinib in pre-BCR+ ALL. Consequently, in mouse xenograft models of pre-BCR+ ALL, ibrutinib treatment significantly prolonged survival. Combination treatment of ibrutinib with dexamethasone or vincristine demonstrated synergistic activity against pre-BCR+ ALL. These data corroborate ibrutinib as a promising targeted agent for pre-BCR+ ALL and highlight the importance of ibrutinib effects on alternative kinase targets.
引用
- Kim E, Hurtz C, Koehrer S, et al. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2016. PMID: 28031181. doi:10.1182/blood-2016-06-722900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。